Global Health Ventures Closes the First Phase of the Previously Announced $2,000,000 Private Placement

Global Health Ventures Inc. (OTCBB: GHLV) or the "Company", a Specialty Pharma is pleased to announce today that it has completed a non-brokered private placement of units (the "Units"). The Company issued 800,000 Units at a price of $0.75 per Unit for total gross proceeds of $600,000 (the "Private Placement"). Each Unit consists of one Common Share of the Company and one share purchase Warrant. Each Warrant is exercisable to purchase one common share of the company at a price of $1 per share at any time or before October 28, 2011.

These securities have not and will not been registered under the Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States without registration or an applicable exemption from applicable registration requirements in the United States.

The Company is presently negotiating the terms of the remaining funds and although there is no guarantee, management is quite confident of its success. The Company will use the proceeds of this financing to carry out the clinical trials needed for approval of its lead life-style pharmaceutical products, (X-Excite), a male sexual enhancement drug. X-Excite is a new formulation of an existing sexual enhancement drug, which is designed to rapidly enter the blood system, maximizing its efficacy and performance. The drug is developed to work sublingually, thus having a more rapid mode of action, and bypassing all the inconveniences and many side effects associated with other application routs. Life style products, such as Viagra(TM), Cialis(TM) and Levitra(TM), etc are highly lucrative products for pharmaceutical companies. This trend shall continue and with the arrival of the new products, the former products shall loose a substantial portion of their market to the arrival of better and less side effects products. The need for a convenient, low cost and fast acting formulation is highly desirable and the Company believes to be able to take a lion share of the market.

"As a result of the financing, our balance sheet will be significantly strengthened and the achievement of our goals are further materialized," stated Dr. Hassan Salari, Global Health President and CEO.

About Global Health Ventures Inc.

Global Health Ventures Inc. (the "Company") is a specialty pharma with focus on the Over-The-Counter drug market. The Company has a new proprietary platform technology that delivers many approved drugs via the sublingual (under the tongue) route. This unique method delivers low dose drugs directly to the blood stream, bypassing all the side effects of digestive and liver system breakdowns, while maintaining product efficacy. The Company currently has five products in late stage development and several more underway.

Safe Harbor Statement

This press release includes forward-looking statements that involve a number of risks and uncertainties, including the success of the products in commercializing and developing. Further, the risks involve the ability of the Company to raise capital to fund its operations and the capital requirements for the development and marketing of its products. Investors are encouraged to review the risk factors listed or described from time to time in the Company's filings (10K) with the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Contacts:
Global Health Ventures Inc.
Dr. Hassan Salari, Ph.D.
President & CEO
Toll free: 1-877-448 4620 or + 604-324 4844
604-324-4845 (FAX)
hsalari@globalhealth3000.com
www.globalhealth3000.com

SOURCE: Global Health Ventures Inc.

mailto:hsalari@globalhealth3000.com
http://www.globalhealth3000.com

Related terms: ceo, drugs, health, market, marketing, pharmaceuticals, president, Private Placement, products, securities, technology